Funding Accelerates the Development of Compliance Automation SolutionsLOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / LighthouseAI™, an industry...
Second Quarter Revenue Increased 18% to $147 MillionFORT MYERS, FL / ACCESSWIRE / August 8, 2023 / NeoGenomics, Inc. (NASDAQ:NEO)...
Post-Hoc Analysis of SOLOIST-WHF Clinical Data Published in Journal of the American College of Cardiology: Heart Failure Risk Reductions of...
Chiesi Group announces mid-year turnover of €1,497 millionSubstantial growth of each of Chiesi’s business areasEurope remains the biggest market, followed...
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected...
Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:...
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer...
Approximately 1.4 million Canadian women have PCOS, and this unique soft-gel capsule is approved to help them manage their symptoms...
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell...
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g.,...
UPPSALA, Sweden, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Baylor...
Resmetirom new drug application (NDA) submitted to the U.S. Food and Drug AdministrationNASH disease education and market development activities expand to...
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- LifeSci Consulting, a boutique strategy consulting and advisory firm focused solely on...
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
FARMINGTON HILLS, Mich., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused...
First dual coronavirus-norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against...
Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan...
Recursion's Pipeline Recursion's internal pipeline as of Q2 2023Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein...
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc....
On track for Biologics License Application (BLA) submission in third quarter of 2023 Proceeds from $25 million registered direct offering...